Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Yatin Suneja
GUGG

Yatin Suneja

Guggenheim
Wall Street Analyst
★★☆☆☆
#2903
on 13Foresight · ranked by our own returns
44%
Success Rate
-4.0%
Average Return
46 of 105 calls profitable · +20.8% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 44% of Yatin Suneja's ratings turned a profit when each position was held for 1 year — averaging -4.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

147 Buy 7 Hold 0 Sell
Yatin's Stock Coverage 50 ratings · 2026-11-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
DBVT
DBV Technologies SA - American
 Oct 29, 2026 BUY Buy
+143.7% avg upside
15 analysts
$46.00
384.73% Upside
 +15.6% ·
PHAT
Phathom Pharmaceuticals
 Oct 29, 2026 BUY Strong Buy
+316.5% avg upside
15 analysts
$22.00
283.28% Upside
 -15.6% ·
AVTX
Avalo Therapeutics
 Oct 23, 2026 HOLD Strong Buy
+561.5% avg upside
20 analysts
 — +11.3% ·
ARGX
Argenx Se
 Oct 22, 2026 BUY Strong Buy
-8.2% avg upside
48 analysts
$1120.00
25.36% Upside
 +12.7% ·
ABVX
Abivax SA Sponsored ADR
 Oct 20, 2026 BUY Strong Buy
+54.7% avg upside
16 analysts
$175.00
102.13% Upside
 -2.6% ·
EYPT
EyePoint Pharmaceuticals
 Oct 19, 2026 HOLD Buy
+3222.8% avg upside
21 analysts
 — -25.0% ·
TRAX
First Tracks Biotherapeutics Inc
 Oct 12, 2026 BUY Strong Buy
+64.6% avg upside
11 analysts
$100.00
121.85% Upside
 +48.4% ·
ZURA
Zura Bio
 Oct 02, 2026 BUY Strong Buy
+292.3% avg upside
13 analysts
$20.00
395.04% Upside
 -65.2% ·
KRSA
Korsana Biosciences
 Sep 28, 2026 BUY Strong Buy
+27.8% avg upside
7 analysts
$70.00
132.24% Upside
 +0.7% ·
CLDX
Celldex
 Sep 22, 2026 BUY Strong Buy
+42.9% avg upside
28 analysts
$100.00
232.20% Upside
 -8.0% ·
SION
Sionna Therapeutics, Inc.
 Sep 15, 2026 HOLD Buy
+461.5% avg upside
12 analysts
 — -48.0% ·
ROIV
Roivant Sciences
 Sep 08, 2026 BUY Strong Buy
+10.7% avg upside
19 analysts
$46.00
24.58% Upside
 -2.8% ·
ALMS
Alumis Inc.
 Sep 02, 2026 HOLD Strong Buy
+361.9% avg upside
11 analysts
 — -40.8% ·
LTGO
Latigo Biotherapeutics, Inc.
 Sep 01, 2026 BUY Strong Buy
+313.4% avg upside
3 analysts
$50.00
258.45% Upside
 -39.3% ·
SYRE
Spyre Therapeutics
 Aug 26, 2026 BUY Strong Buy
+0.9% avg upside
25 analysts
$130.00
34.61% Upside
 +11.4% ·
CABA
Cabaletta Bio
 Aug 13, 2026 BUY Strong Buy
+832.3% avg upside
16 analysts
$16.00
959.67% Upside
 -44.6% ·
ZBIO
Zenas BioPharma, Inc.
 Aug 13, 2026 BUY Strong Buy
+52.5% avg upside
11 analysts
$55.00
93.70% Upside
 -1.7% ·
IMUX
Immunic
 Aug 11, 2026 BUY Strong Buy
+399.8% avg upside
23 analysts
$70.00
832.13% Upside
 -49.9% ·
ORKA
Oruka Therapeutics
 Aug 10, 2026 BUY Strong Buy
+37.2% avg upside
16 analysts
$200.00
106.41% Upside
 -0.0% ·
AXSM
Axsome Therapeutics
 Aug 10, 2026 BUY Strong Buy
+63.9% avg upside
30 analysts
$275.00
90.44% Upside
 -34.0% ·
CLYM
Climb Bio
 Aug 07, 2026 BUY Strong Buy
+120.9% avg upside
21 analysts
$35.00
241.48% Upside
 -21.4% ·
PRAX
Praxis Precision Medicines
 Aug 06, 2026 BUY Strong Buy
+99.2% avg upside
25 analysts
$800.00
179.81% Upside
 -10.0% ·
OCS
Oculis Holding
 Aug 06, 2026 BUY Strong Buy
+367.7% avg upside
11 analysts
$45.00
444.86% Upside
 -38.5% ·
XENE
Xenon
 Aug 06, 2026 BUY Strong Buy
+53.0% avg upside
28 analysts
$90.00
140.53% Upside
 -35.4% ·
DNTH
Dianthus Therapeutics
 Aug 05, 2026 BUY Strong Buy
+23.4% avg upside
32 analysts
$200.00
142.80% Upside
 -21.6% ·
REGN
Regeneron
 Aug 03, 2026 BUY Strong Buy
-12.1% avg upside
60 analysts
$1030.00
10.95% Upside
 +20.6% ·
NBIX
Neurocrine
 Jul 31, 2026 BUY Strong Buy
+27.3% avg upside
37 analysts
$222.00
51.88% Upside
 -13.5% ·
BIIB
Biogen
 Jul 21, 2026 BUY Strong Buy
+6.6% avg upside
53 analysts
$280.00
10.44% Upside
 +24.8% ·
IMVT
Immunovant
 May 26, 2026 BUY Strong Buy
+38.4% avg upside
25 analysts
$62.00
112.58% Upside
 +6.6% ·
SABS
SAB Biotherapeutics
 May 13, 2026 BUY Strong Buy
+218.4% avg upside
14 analysts
$15.00
347.86% Upside
 -23.5% ·
IFRX
InflaRx
 May 08, 2026 BUY Buy
+430.1% avg upside
12 analysts
$14.00
743.40% Upside
 -49.2% ·
STOK
Stoke Therapeutics
 May 07, 2026 BUY Strong Buy
+55.8% avg upside
18 analysts
$60.00
128.19% Upside
 -17.5% ·
NMRA
Neumora Therapeutics, Inc.
 May 07, 2026 BUY Buy
+1957.6% avg upside
11 analysts
$14.00
3712.60% Upside
 -76.8% ·
ACET
Adicet Bio
 Mar 13, 2026 BUY Strong Buy
+665.1% avg upside
14 analysts
$100.00
2824.07% Upside
 -58.4% ·
ANAB
AnaptysBio
 Mar 04, 2026 BUY Strong Buy
+48.7% avg upside
26 analysts
$140.00
189.96% Upside
 +20.8% ·
MLTX
MoonLake Immunotherapeutics
 Feb 24, 2026 BUY Strong Buy
+158.9% avg upside
20 analysts
$20.00
69.85% Upside
 -36.6% ·
LRMR
Larimar Therapeutics
 Sep 29, 2025 BUY Strong Buy
+621.1% avg upside
22 analysts
$26.00
952.58% Upside
 -7.1% ·
ACAD
ACADIA Pharmaceuticals
 Feb 27, 2025 HOLD Strong Buy
+71.5% avg upside
43 analysts
$20.00
2.80% Downside
 +27.0% ·
SRZN
Surrozen
 Jan 03, 2025 BUY Buy
+33.6% avg upside
8 analysts
$45.00
54.96% Upside
 +26.6% ·
QTTB
Q32 Bio
 Dec 11, 2024 HOLD Strong Buy
+523.8% avg upside
28 analysts
 — -46.6% ·
SEELQ
Seelos Therapeutics
 Sep 21, 2023 HOLD Buy
+4638571328.6% avg upside
10 analysts
 — · ·
RLMD
Relmada Therapeutics
 Aug 08, 2023 HOLD Buy
+273.3% avg upside
15 analysts
 — -9.4% ·
BTAIQ
Bioxcel Therapeutics
 Jul 17, 2023 HOLD Strong Buy
+186224.8% avg upside
12 analysts
 — · ·
BLCO
Bausch + Lomb Corporation
 May 31, 2022 BUY Buy
+7.6% avg upside
20 analysts
$24.00
20.00% Upside
 +5.0% ·
XCUR
Exicure
 May 15, 2020 BUY Buy
+9256.5% avg upside
4 analysts
$9.00
791.17% Upside
 · ·
AGIO
Agios Pharma
 Jul 20, 2018 BUY Strong Buy
+99.0% avg upside
30 analysts
$123.00
302.62% Upside
 -48.6% ·
LITS
Lite Strategy
 Jul 13, 2018 BUY Buy
+865.5% avg upside
13 analysts
$12.00
971.43% Upside
 · ·
CBIO
Crescent Biopharma
 Dec 12, 2017 BUY Strong Buy
+73.7% avg upside
17 analysts
$32.00
137.35% Upside
 · ·
TGTX
TG Therapeutics
 Oct 18, 2017 BUY Strong Buy
-30.0% avg upside
20 analysts
 — -29.8% ·
OMER
Omeros
 Aug 13, 2014 BUY Buy
+13.6% avg upside
14 analysts
 — -3.4% ·
🔒 45 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Yatin Suneja — Frequently Asked Questions
How accurate are Yatin Suneja's stock ratings?
Based on the calls 13Foresight could measure, about 43% of Yatin's ratings were profitable over a one-year hold, with an average return of -4.3% per rating, or -7.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Yatin ranked on 13Foresight?
Yatin Suneja is currently ranked #2903 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Yatin cover?
Yatin most recently has ratings on DBVT, PHAT, AVTX, ARGX, ABVX, EYPT, TRAX, ZURA, KRSA, CLDX, SION, ROIV and 38 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.